Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Humacyte (HUMA) Shares Outstanding (Diluted Average) (2024 - 2025)

Humacyte has reported Shares Outstanding (Diluted Average) over the past 2 years, most recently at $158.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $158.2 million for Q4 2025, up 33.49% from a year ago — trailing twelve months through Dec 2025 was $158.2 million (up 33.49% YoY), and the annual figure for FY2025 was $158.2 million, up 33.49%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $158.2 million at Humacyte, roughly flat from $158.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for HUMA hit a ceiling of $158.3 million in Q3 2025 and a floor of $108.2 million in Q1 2024.